Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel disease – authors' reply

Publisher: John Wiley & Sons Inc

E-ISSN: 1365-2036|42|7|940-941

ISSN: 0269-2813

Source: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.7, 2015-10, pp. : 940-941

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract